The FDA has delayed its target decision date for Orca Bio’s blood cancer cell therapy candidate Orca-T by three months to ...
Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell ...
The Food and Drug Administration (FDA) has extended the review period for Orca-T in the treatment of patients with hematologic malignancies.
The FDA has extended the deadline to review Orca-T for the treatment of myelodsyplastic syndromes and acute leukemias with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results